Clinical trial
Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy…
NCT00286416 · Scripps Clinic, Other · Unknown status
Key facts
| NCT number | NCT00286416 |
|---|---|
| Title | Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma |
| Official title | Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-Morbid Conditions of Aspirin Exacerbated Respiratory Disease(AERD) and Allergic Asthma and Rhinitis. |
| Lead sponsor | Scripps Clinic, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Asthma, Allergic Rhinitis |
| Intervention type | Drug |
| Interventions | omalizumab (Xolair) |
| Enrollment | 60 |
| Start date | Jan 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Feb 3, 2006 |
| Last update posted | Nov 7, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: